Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06541860
DAratumumab and REvlimid REfractory MM
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
View on ClinicalTrials.gov
Summary
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Official title: Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2023-08-21
Completion Date
2028-08-21
Last Updated
2024-08-07
Healthy Volunteers
No
Conditions
Locations (1)
Irccs San Matteo Pavia
Pavia, PV, Italy